Ubrelvy Does Not Cause Panic Attacks
Based on the FDA drug label and available safety data, panic attacks are not a recognized adverse effect of Ubrelvy (ubrogepant). The FDA-approved prescribing information does not list panic attacks, anxiety, or psychiatric symptoms among the documented adverse events 1.
What the Evidence Shows
FDA-Approved Safety Profile
The FDA label for Ubrelvy identifies specific adverse events to monitor 1:
- Hypersensitivity reactions (requiring discontinuation)
- Hypertension (new onset or worsening of pre-existing)
- Raynaud's phenomenon (new onset or worsening)
Notably absent from this list are any psychiatric or anxiety-related adverse events, including panic attacks.
Post-Marketing Surveillance Data
A comprehensive analysis of the FDA Adverse Event Reporting System (FAERS) database examined 2,067 reports where Ubrelvy was the primary suspected medication and identified 6,190 adverse events 2. This large-scale post-marketing surveillance detected:
- Common expected effects: migraine, nausea, somnolence, oral paresthesia, dizziness
- Newly identified effects: hemiparesis, mental impairment, dysstasia, tinnitus, chest pain, cold sweat, neck pain
Panic attacks were not identified as a signal in this comprehensive safety analysis 2.
Clinical Trial Safety Data
The pivotal Phase 3 trials (Study 1 and Study 2) involving over 2,200 patients treated with Ubrelvy did not report panic attacks as an adverse event 1. The most recent prodromal phase trial (PRODROME) with 477 participants similarly showed no psychiatric adverse events 3.
Clinical Implications
If a patient reports panic attacks while taking Ubrelvy, consider alternative explanations:
- Migraine-associated anxiety: Panic attacks can be part of the migraine prodrome or occur comorbidly with migraine disorder
- Coincidental timing: Panic disorder affects 2-3% of the population and may develop independently
- Medication interaction: Review all concomitant medications, particularly if the patient is taking other CNS-active drugs
- Misattribution: The patient may be experiencing other Ubrelvy side effects (dizziness, chest pain) that mimic panic symptoms
Bottom Line
There is no evidence from FDA labeling, clinical trials, or post-marketing surveillance that Ubrelvy causes panic attacks. The medication's safety profile focuses on hypersensitivity reactions, blood pressure changes, and Raynaud's phenomenon—not psychiatric effects 1, 2. If panic symptoms occur, investigate other causes rather than attributing them to Ubrelvy.